Fulltext

First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis

Kasenda, B. ; Ferreri, A. J. M. ; Marturano, E. ; Forst, D. ; Bromberg, J. ; Ghesquieres, H. ; Ferlay, C. ; Blay, J. Y. ; Hoang-Xuan, K. ; Pulczynski, E. J. ; Fosså, A. ; Okoshi, Y. ; Chiba, S. ; Fritsch, K. ; Omuro, A. ; O'Neill, B. P. ; Bairey, O. ; Schandelmaier, S. ; Gloy, V. ; Bhatnagar, N. ; Haug, S. ; Rahner, S. ; Batchelor, T. T. ; Illerhaus, G. ; Briel, M.

In: Annals of Oncology, 2015, vol. 26, no. 7, p. 1305-1313

Add to personal list
    Title
    • First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
    Author
    • Kasenda, B.. Department of Oncology, University Hospital of Basel, Basel
    • Ferreri, A. J. M.. Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy
    • Marturano, E.. Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy
    • Forst, D.. Partners Neurology Residency Program, Harvard Medical School, Boston, USA
    • Bromberg, J.. Department of Neuro-Oncology, Daniel den Hoed Cancer Center, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    • Ghesquieres, H.. Department of Hematology, Centre Léon Bérard, University of Lyon, Lyon
    • Ferlay, C.. Department of Hematology, Centre Léon Bérard, University of Lyon, Lyon
    • Blay, J. Y.. Department of Hematology, Centre Léon Bérard, University of Lyon, Lyon
    • Hoang-Xuan, K.. Department of Neurology Mazarin, LOC National Expert Center, APHP, IHU, UPMC, CRICM, GH Pitié-Salpêtrière, Paris, France
    • Pulczynski, E. J.. Department of Haematology, Nordic Lymphoma Group, University Hospital Aarhus, Aarhus, Denmark
    • Fosså, A.. Norwegian Department of Oncology, Nordic Lymphoma Group, Radium Hospital, Oslo, Norway
    • Okoshi, Y.. Faculty of Medicine, Department of Hematology, University of Tsukuba, Tsukuba, Japan
    • Chiba, S.. Faculty of Medicine, Department of Hematology, University of Tsukuba, Tsukuba, Japan
    • Fritsch, K.. Department of Hematology/Oncology, University Hospital Freiburg, Freiburg, Germany
    • Omuro, A.. Department of Neurology Mazarin, LOC National Expert Center, APHP, IHU, UPMC, CRICM, GH Pitié-Salpêtrière, Paris, France
    • O'Neill, B. P.. Department of Neurology, Mayo Medical School, Rochester, USA
    • Bairey, O.. Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Tel Aviv
    • Schandelmaier, S.. Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
    • Gloy, V.. Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
    • Bhatnagar, N.. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
    • Haug, S.. Psychiatry and Psychotherapy, University Hospital Freiburg, Freiburg
    • Rahner, S.. Medical Faculty, University of Freiburg, Freiburg, Germany
    • Batchelor, T. T.. Partners Neurology Residency Program, Harvard Medical School, Boston, USA
    • Illerhaus, G.. Stuttgart Cancer Center, Eva-Mayr-Stihl Tumor Center, Stuttgart, Germany
    • Briel, M.. Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Annals of Oncology, 2015, vol. 26, no. 7, p. 1305-1313. Oxford University Press
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:290042
    Summary
    Evidence for prognosis and treatment of elderly patient with primary central nervous system is limited. High-dose methotrexate should be applied whenever possible, especially combination with oral alkylating agents is a promising approach. Further combinations with other intravenous drugs do not seem to improve outcome. More prospective trials designed for elderly PCNSL patients are warranted